Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early vs Late Anticoagulation in AIS with NVAF
NCT06057467Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban, dabigatran, apixaban and edoxaban in ischemic stroke and Atrial fibrillation (AFib) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Early neurological deterioration before discharge. Started Sep 2023; status: recruiting.
02
Drugs
rivaroxabandabigatranapixabanedoxaban
03
Conditions
ischemic strokeAtrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06057467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057467.